Novai

Novai
Led by Biotech, Finance, and Pharmaceutical Veterans, Novai has been developing DARC (Detection of Apoptosing Retinal Cells) for over 10 years and has already received over £4m from the Wellcome Trust and UCL to take it to Phase 2 clinical trials (132 Patients to date). DARC combines a patented biomarker and state of the art AI algorithm which allows pharmaceutical companies to reduce the time, cost and risk of developing new drugs. Novai aims to reduce the clinical drug development period from years to months, as well as catch and monitor disease progression in trial patients.
Business Highlights
lock
Video
lock
Investment Deck
lock
Team
lock

03Other opportunities

SFC Angel Fund XIII SEIS

SFC Angel Fund XIII SEIS

Invest under SEIS in high potential start-ups.
Fund Size £50m SEIS
SFC Angel Fund XI EIS

SFC Angel Fund XI EIS

Invest in SFC’s portfolio stars.
Fund Size £20m EIS

Sapien Health

Remote health coaching for patients undergoing surgery.
Raising TBD EIS

Stablepharma

A world-changing invention for the stabilisation of vaccines.
Raising TBD EIS